Suk Hyun Lee1, Sangwon Han1, Hyo Sang Lee1, Sun Young Chae1, Jong Jin Lee1, Dong Eun Song2, Jin-Sook Ryu1. 1. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736 Korea. 2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
PURPOSE: The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence (18)F-fluoro-2-deoxyglucose ((18)F-FDG) avidity. METHODS: We retrospectively reviewed 55 patients who underwent BRAF analysis from biopsy-confirmed PTC and (18)F-FDG positron emission tomography/computed tomography within 6 months before undergoing thyroid surgery from September 2008 to August 2014. Tumors were considered to be (18)F-FDG avid if the uptake was greater than that of the liver. (18)F-FDG uptake of PTCs was also analyzed semiquantitatively using SUVmax. The association between (18)F-FDG avidity and clinicopathologic variables (age, tumor size, perithyroidal extension, cervical lymph node status, and BRAF mutation status) was investigated. RESULTS: Twenty-nine (52.7 %) of 55 patients had (18)F-FDG-avid PTCs. PTCs with the BRAF mutation showed higher (18)F-FDG avidity (24/38, 63.2 %) than those without (5/17, 29.4 %). The BRAF mutation (p = 0.025) and tumor size (p = 0.003) were significantly associated with (18)F-FDG avidity in univariate analysis, and the BRAF mutation status remained significant after adjusting for tumor size in multivariate analysis (p = 0.015). In the subgroup of tumor size ≥ 1 cm, the BRAF mutation was the only factor significantly associated with (18)F-FDG avidity (p = 0.021). The mean SUVmax of PTCs with the BRAF mutation was significantly higher than that of those without (4.89 ± 6.12 vs. 1.96 ± 1.10, p = 0.039). CONCLUSIONS: The BRAF mutation must be one of the most important factors influencing (18)F-FDG avidity in PTCs, especially in those with a tumor size ≥ 1 cm.
PURPOSE: The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence (18)F-fluoro-2-deoxyglucose ((18)F-FDG) avidity. METHODS: We retrospectively reviewed 55 patients who underwent BRAF analysis from biopsy-confirmed PTC and (18)F-FDG positron emission tomography/computed tomography within 6 months before undergoing thyroid surgery from September 2008 to August 2014. Tumors were considered to be (18)F-FDG avid if the uptake was greater than that of the liver. (18)F-FDG uptake of PTCs was also analyzed semiquantitatively using SUVmax. The association between (18)F-FDG avidity and clinicopathologic variables (age, tumor size, perithyroidal extension, cervical lymph node status, and BRAF mutation status) was investigated. RESULTS: Twenty-nine (52.7 %) of 55 patients had (18)F-FDG-avid PTCs. PTCs with the BRAF mutation showed higher (18)F-FDG avidity (24/38, 63.2 %) than those without (5/17, 29.4 %). The BRAF mutation (p = 0.025) and tumor size (p = 0.003) were significantly associated with (18)F-FDG avidity in univariate analysis, and the BRAF mutation status remained significant after adjusting for tumor size in multivariate analysis (p = 0.015). In the subgroup of tumor size ≥ 1 cm, the BRAF mutation was the only factor significantly associated with (18)F-FDG avidity (p = 0.021). The mean SUVmax of PTCs with the BRAF mutation was significantly higher than that of those without (4.89 ± 6.12 vs. 1.96 ± 1.10, p = 0.039). CONCLUSIONS: The BRAF mutation must be one of the most important factors influencing (18)F-FDG avidity in PTCs, especially in those with a tumor size ≥ 1 cm.
Authors: Monica Zerilli; Giovanni Zito; Anna Martorana; Maria Pitrone; Daniela Cabibi; Francesco Cappello; Carla Giordano; Vito Rodolico Journal: Mod Pathol Date: 2010-05-14 Impact factor: 7.842
Authors: Bo Hyun Kim; In Joo Kim; Sang Soo Kim; Seong-Jang Kim; Chang Hun Lee; Yong-Ki Kim Journal: Cancer Biother Radiopharm Date: 2010-06 Impact factor: 3.099
Authors: Marcello Tiseo; Massimo Ippolito; Maura Scarlattei; Pietro Spadaro; Sebastiano Cosentino; Fiorenza Latteri; Livia Ruffini; Marco Bartolotti; Beatrice Bortesi; Claudia Fumarola; Cristina Caffarra; Andrea Cavazzoni; Roberta R Alfieri; Pier Giorgio Petronini; Roberto Bordonaro; Paolo Bruzzi; Andrea Ardizzoni; Hector J Soto Parra Journal: Cancer Chemother Pharmacol Date: 2013-11-21 Impact factor: 3.333
Authors: Angela van Baardwijk; Christophe Dooms; Robert Jan van Suylen; Erik Verbeken; Monique Hochstenbag; Cary Dehing-Oberije; Dennis Rupa; Silvia Pastorekova; Sigrid Stroobants; Ulrich Buell; Philippe Lambin; Johan Vansteenkiste; Dirk De Ruysscher Journal: Eur J Cancer Date: 2007-05-23 Impact factor: 9.162
Authors: Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Jae Won Chang; Ki Wan Park; Jae Hyung Heo; Seung-Nam Jung; Lihua Liu; Sung Min Kim; In Sun Kwon; Bon Seok Koo Journal: World J Surg Date: 2018-01 Impact factor: 3.352
Authors: Katalin Gábora; Elena Bărbuş; Claudiu Peştean; Maria Iulia Larg; Eduard Alexandru Bonci; Claudiu Ioan Bădulescu; Andra Piciu Journal: Clujul Med Date: 2018-10-30
Authors: Le Ngoc Ha; Amir Iravani; Nguyen Thi Nhung; Ngo Thi Minh Hanh; Febby Hutomo; Mai Hong Son Journal: Cancer Imaging Date: 2021-01-07 Impact factor: 3.909